Background/aim: Pompe disease (acid maltase deficiency, glycogen storage disease type II, OMIM #606800) is an autosomal recessive disorder characterized by lysosomal acid-α-glucosidase deficiency. The infantile-onset type of the disease is mainly characterized by cardiomegaly, hypotonia, and a high mortality rate. This study aimed to create a national consensus about infantile-onset Pompe disease (IOPD) to raise awareness among clinicians and standardize diagnosis and treatment approaches in Türkiye. Materials and methods: The Gazi University Division of Metabolic Diseases and Nutrition developed this expert opinion consensus and expanded it to include metabolism specialists across Türkiye. A systematic literature review was performed, and the Delphi method was used to evaluate the results. Results: Seventeen conclusive questions were produced about clinical presentation, diagnosis, and treatment, and 14 reached a consensus. Consensus was reached that general hypotonia is one of the most important findings, and agreement was also achieved on the starting dose of treatment for presymptomatic patients. The contributors agreed that gene therapy is a good treatment option for IOPD in the future. Conclusion: The topics related to this consensus will help physicians in Türkiye and elsewhere with high incidence rates of IOPD,especially regarding diagnosis and treatment decisions.
6 August 2024 in Journal of Pediatric Endocrinology and Metabolism
Objectives: Glycogen storage disease type V is caused by the mutations in muscle glycogen phosphorylase gene. This is the first report which DL-3-hydroxybutyric acid was used in combination with modified Atkins diet for the treatment of a patient with glycogen storage disease type V and quadriceps femoris shear wave elastography was performed to evaluate the treatment efficacy. Case presentation: A 13-year-old girl was referred with fatigue and muscle cramps with exercise and there were no pathological findings in physical examination. Creatine kinase levels with 442 U/L. No phosphorylase enzyme activity was detected in muscle biopsy, a homozygous c.1A>G (p.M1V) pathogenic mutation was found in PYGM gene. She was started on DL-3-hydroxybutyric acid and modified Atkins diet at age 16. Her walking and stair climbing capacity increased, the need for rest during exercise decreased. The stiffness of the quadriceps femoris exhibited a reduction. Conclusions: DL-3-hydroxybutyric acid and modified Atkins diet may provide an alternative fuel and shear wave elastography may be useful in demonstrating treatment efficacy. More clinical and pre-clinical studies are obviously needed to reach more definite conclusions.
16 February 2026 in Orphanet Journal of Rare Diseases
Background: Gyrate atrophy of the choroid and retina (GACR) is a rare amino acid metabolism disorder. Night blindness, cataracts, vision loss, and impaired cognitive functions can be seen. An arginine-restricted diet, combined with pyridoxine, lysine, proline, or creatine supplementation, can be used in conjunction with treatments for ophthalmological findings. Methods: Patients followed by the Gazi University Faculty of Medicine, Department of Pediatric Metabolism and Nutrition, and Department of Ophthalmology who were genetically or biochemically diagnosed with GACR were included in the study. The patients’ medical records were retrospectively reviewed between 2000 and 2023. Results: Seven patients with a mean age of 18.08 ± 8.6 years and a mean age at diagnosis of 10.4 ± 5.6 years were included. The earliest diagnosed patient was 15 months old. All patients had high plasma ornithine levels at the time of diagnosis, and they were all started on an arginine-restricted diet. Ophthalmological treatments were decided on a patient-specific basis. Conclusions: GACR is easily recognizable, but there is still no consensus on treatment modalities. The patients primarily present with progressive ophthalmological findings. An arginine-restricted diet is combined with supplementation with pyridoxine, lysine, proline, or creatine to improve metabolic control. Ophthalmological treatments are mainly applied to reduce cystoid macular edema. Early diagnosis and early initiation of therapy should be aimed at patients, and a multidisciplinary approach should be demonstrated both in diagnosis and follow-up.
Ömrünü eğitime ve tıp bilimine adamış, pediatri alanında kendi eğitimini tamamlayan ve hala sürdüren yazarlarımız ile iki yıldır süren çalışmalarımızın meyvesi olan kitabımız için çok mutluyuz. Yedi yaşından beri gece gündüz demeden çalışan, pediatri uzmanlığını ve yan dalını hakkıyla tamamlamak için çok emek harcayan arkadaşlar, tecrübelerini ve öğrendiklerini eğitime yeni başlayan meslektaşlarına aktarmak için bir kılavuz olacak bu kitabı hazırladık. Bu kitabın; pratisyen hekim, pediatri asistanları ve uzmanlarına klinik pratikte en sık karşılaşacakları hastalıkların tanısı, kliniği ve tedavisi konusunda hızlıca bilgilere ulaşabilmeleri açısından çok büyük kolaylık sağlayacağına inanıyoruz. Bu nedenle acillerde, polikliniklerde ve servislerde sıkça başvurulan bir kitap olacağını düşünüyoruz.
Inherited metabolic disorders (IMDs) are traditionally considered pediatric-onset conditions; however, an increasing number of patients are diagnosed in adolescence and adulthood, often presenting with heterogeneous and nonspecific clinical manifestations. This study aimed to describe the clinical spectrum, biochemical findings, genetic diagnoses, and management approaches in transition-age and adult patients diagnosed with IMDs. This retrospective analysis included 18 patients diagnosed with IMDs. Patients aged ≥16 years were included and defined as transition-age individuals to account for the overlap between pediatric and adult presentations. Demographic, clinical, biochemical, and genetic data were collected, and treatment strategies were recorded. Diagnostic evaluation was based on disease specific biochemical assays supplemented by molecular genetic testing. The cohort included 10 females and 8 males, with a mean age at diagnosis of 34.2 years (range: 16–61 years). The diagnostic spectrum was heterogeneous, with alkaptonuria (n = 4) as the most frequent diagnosis, followed by glycogen storage disease type V (n = 2), while the remaining disorders were individually rare. Muscle-related symptoms, including exercise intolerance, myalgia, or rhabdomyolysis, were observed in 8 patients (44.4%), and elevated creatine kinase levels were detected in 9 patients (50.0%). A definitive molecular diagnosis was established in all patients, allowing implementation of disease-specific treatment or targeted management strategies in the majority of cases. Adult-onset IMDs show marked clinical and genetic heterogeneity and frequently present with nonspecific neuromuscular or neurological findings. These results highlight the importance of considering IMDs in adult patients with unexplained multisystem involvement and underscore the role of integrated biochemical and genetic evaluation for accurate diagnosis and timely management.
This study aimed to assess obstetric healthcare providers’ awareness and knowledge of IMDs and their prenatal manifestations. Participants were surveyed using an online questionnaire about clinical and imaging features observed in fetuses and neonates with IMDs, their approach to clinical management when an IMD is suspected in the fetus, and the management of pregnant women with IMDs. 270 obstetricians participated, with a mean age of 32.5 ± 7.1 years. Most participants (81.5%) had less than 5 years of experience. The more experienced group was more likely to consider their knowledge of antenatal IMD diagnosis and follow-up to be adequate (p = 0.015). Participants in the educated group believed that IMDs could present symptoms during the intrauterine period (p = 0.003). Improving obstetricians’ awareness about IMDs to optimize prenatal counseling, referral, and perinatal planning is crucial. Theoretical and practical training in IMDs should be incorporated into obstetrics residency programs to enable timely diagnosis and early treatment initiation.